MENU
NKTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Nkarta (NKTX) Ownership - Who owns Nkarta?

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases... Show more

Profile

Industry
N/A
Address
1150 Veterans Boulevard
Phone
+1 905 407-1049
Employees
150
Web
https://www.nkartatx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
141.92M
P/E Ratio
N/A
Total Cash
283.06M
Projected Growth
N/A
Total Debt
85.45M
Revenue
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash/Share
3.99
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

NKTX
Capitalization
142M
P/E Ratio
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash
283M
Total Cash/Share
3.99
Total Debt
85.4M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
431M
P/B Ratio
0.32
Cash Flow
N/A
Earnings
-1.83
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
12.91
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-119.34M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-23.59
Shares Held By Institutions
199M
Shares Outstanding - Current
71M
Total Liabilities
101M
Total Volume MTD
N/A
Value
1
Gain YTD
-26.104
View a ticker or compare two or three
NKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1150 Veterans Boulevard
Phone
+1 905 407-1049
Employees
150
Web
https://www.nkartatx.com